Some pharmacokinetic characteristics of furafylline, a new 1,3,8-trisubstituted xanthine.
After administration of furafylline, a, 1,3,8-trisubstituted xanthine, to beagle dogs at 0.5 and 10 mg kg-1 an elimination half-life 2-10 times longer than that of theophylline was observed. The kinetics were dose-dependent but no phase I metabolites were detected. When the compound was given orally to humans at a dose of 1.3-1.9 mg kg-1 a mean beta elimination half-life of 48.1 +/- 10.8 h was obtained after an initial distribution phase. Evidence of non-linear kinetics for plasma levels below 0.6 microgram ml-1 was also obtained. Other 1,3,8-trisubstituted xanthines, may also have a lower elimination rate than theophylline.
D000328:Adult; D000818:Animals; D004285:Dogs; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006207:Half-Life; D006801:Humans; D007700:Kinetics; D008297:Male; D008657:Metabolic Clearance Rate; D013806:Theophylline / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology
D013806:Theophylline; C050131:furafylline